Drugs / hMaxi-K
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01870037 | Jan 2013 → Jun 2017 | overactive bladder | Urovant Sciences GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00495053 | Apr 2007 → Jul 2008 | overactive bladder | Urovant Sciences GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02713789 Comparator | Apr 2015 → Aug 2017 | erectile dysfunction | Urovant Sciences GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hMaxi-K | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01870037 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “uses human gene transfer (called hMaxi-K)” NCT00495053 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT01870037 ↗ |